Del. Suit Alleges Insider Trades Worth $171M By Nektar Execs
Officers and directors of Nektar Therapeutics misled the public about the prospects of the company's cancer-fighting immunotherapy treatment and then sold more than $171 million worth of their stock before the...To view the full article, register now.
Already a subscriber? Click here to view full article